IFP Advisors
ADCT icon

IFP Advisors’s ADC Therapeutics ADCT Stock Holding History

IFP Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$117 Sell
96
-44
-31% -$51 ﹤0.01% 4962
2026
Q2 		$150 Buy
140
+110
+367% +$321 ﹤0.01% 4902
2026
Q1 		$112 Sell
30
-39
-57% -$154 ﹤0.01% 4720
2025
Q4 		$244 Buy
69
+39
+130% +$158 ﹤0.01% 4442
2025
Q3 		$120 Hold
30
– – ﹤0.01% 4513
2025
Q2 		$80 Buy
+30
New +$63 ﹤0.01% 4750

Other funds holding ADCT

DIM
DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
SCM
Saxony Capital Management St. Louis, Missouri $238M AUM 19.13% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

IFP Advisors's ADCT Position: Q3 2026 in Review

IFP Advisors reduced its ADC Therapeutics (ADCT) stake by 31% in Q3 2026, selling an estimated $51 and leaving 96 shares worth $117. The position accounts for ﹤0.01% of the portfolio, ranked #4962.

IFP Advisors first reported a position in ADCT in Q2 2025 and has held it in 6 quarters since. The position peaked at $244 in Q4 2025. 8 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • IFP Advisors held 96 shares of ADC Therapeutics worth $117 as of Q3 2026.
  • IFP Advisors sold 44 ADC Therapeutics shares in Q3 2026, an estimated $51.
  • ADC Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4962 holding.
  • IFP Advisors first reported a position in ADC Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • IFP Advisors's ADC Therapeutics position peaked at $244 in Q4 2025.
  • 8 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.